Tag: Pharma & Life Sciences

Following the U.S. Supreme Court’s decision to leave intact the Patent Protection and Affordable Care Act, the development of biosimilars to treat a wide variety of diseases and health conditions is poised to surge. The Act contains important provisions that create a pathway for the FDA to approve “biosimilar” versions of previously approved biotechnology...

The U.S. Supreme Court claimed it was merely applying well-established precedents. But that’s not how many experts view the decision in Mayo Collaborative Services v. Prometheus Laboratories.

The U.S. Court of Appeals for the Federal Circuit on April 16, 2012, in Bayer Schering Pharma AG v. Sandoz Inc., Nos. 2011-1143, -1228 (Yasmin), affirmed a district court's holding that as a matter of law, generic drug makers could not infringe patent claims reciting a method of use of a U.S. Food and Drug...

The U.S. Court of Appeals for the Federal Circuit on April 16, 2012, in Bayer Schering Pharma AG v. Sandoz, Inc., Nos. 2011-1143, -1228 (YASMIN®), affirmed a district court's holding that as a matter of law, generic drug makers could not infringe patent claims reciting a method of use of an FDA-approved...